Sanofi-aventis announced that they have signed an agreement with AgaMatrix Inc. for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes care with the aim to simplify patients’ and healthcare providers’ diabetes management experience. These BGM solutions will be exclusive to sanofi-aventis and will be designed to be synergistic to sanofi-aventis’ diabetes portfolio including popular the insulin’s Apidra and Lantus. Sanofi-aventis expects to commercialize the first products of this partnership by the first half of 2010.
